EP 1119361 A2 20010801 - TREATMENT OF CARCINOMAS USING SQUALAMINE IN COMBINATION WITH OTHER ANTI-CANCER AGENTS OR MODALITIES
Title (en)
TREATMENT OF CARCINOMAS USING SQUALAMINE IN COMBINATION WITH OTHER ANTI-CANCER AGENTS OR MODALITIES
Title (de)
BEHANDLUNG VON KARZINOMEN MIT SQUALAMIN IN KOMBINATION MIT ANDEREN ANTI-TUMOR-AGENZIEN
Title (fr)
TRAITEMENT DES CARCINOMES A BASE DE SQUALAMINE COMBINEE A D'AUTRES AGENTS ANTICANCEREUX
Publication
Application
Priority
- US 9920645 W 19990910
- US 15072498 A 19980910
Abstract (en)
[origin: WO0015176A2] A method for treating a tumor includes a first treatment procedure using a conventional cancer treatment technique, and a second treatment procedure which includes administering an effective amount of squalamine. Synergistically effective amounts are preferred. The first treatment procedure may be a treatment with one or more conventional cytotoxic chemical compounds. As examples, the cytotoxic chemical compound may be a nitrosourea (such as BCNU), cyclophosphamide, doxorubicin, 5-fluorouracil, paclitaxel and its derivatives, cisplatin or other platinum containing cancer treating agents. Alternatively, the first treatment may be a treatment with one or more conventional anti-hormonal agents. As examples, the anti-hormonal agents may be a LHRH (luteinizing hormone releasing hormone) agonist or an anti-androgen such as flutamide, biclutamide, nilutamide, and luprolide. These conventional cancer treatments compounds and the squalamine may be administered by any suitable route. The first treatment procedure may take place prior to the second treatment procedure, after the second treatment procedure, or the two treatment procedures may take place simultaneously. As an alternative, the first treatment procedure may be a conventional radiation treatment regimen. As a further alternative the first treatment procedure may be a combination of treatment with one or more conventional cytotoxic chemical compounds and a conventional radiation treatment regimen.
IPC 1-7
IPC 8 full level
A61K 31/575 (2006.01); A61K 45/00 (2006.01); A61K 31/00 (2006.01); A61K 31/136 (2006.01); A61K 31/166 (2006.01); A61K 31/167 (2006.01); A61K 31/17 (2006.01); A61K 31/198 (2006.01); A61K 31/277 (2006.01); A61K 31/351 (2006.01); A61K 31/407 (2006.01); A61K 31/41 (2006.01); A61K 31/4166 (2006.01); A61K 31/437 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/565 (2006.01); A61K 31/7004 (2006.01); A61K 33/24 (2006.01); A61K 33/42 (2006.01); A61K 45/06 (2006.01); A61P 5/02 (2006.01); A61P 5/28 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP)
A61K 31/00 (2013.01); A61K 31/575 (2013.01); A61P 5/02 (2017.12); A61P 5/28 (2017.12); A61P 35/00 (2017.12)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0015176 A2 20000323; WO 0015176 A3 20000720; AU 6496299 A 20000403; AU 757649 B2 20030227; CA 2343133 A1 20000323; EP 1119361 A2 20010801; EP 1119361 A4 20061004; JP 2002524481 A 20020806
DOCDB simple family (application)
US 9920645 W 19990910; AU 6496299 A 19990910; CA 2343133 A 19990910; EP 99952905 A 19990910; JP 2000569761 A 19990910